Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients (HITOLT)
In a prospective observational study the incidence of Heparin-induced Thrombocytopenia (HIT) Type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns is going to be investigated.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients: a Prospective Multivariate Analysis of Prognostic Factors and Haemostaseological Findings|
|Study Start Date:||January 2010|
|Study Completion Date:||August 2011|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
orthotopic Liver Transplantation
consecutive inclusion of all recipients
The investigators examined the frequency of anti-PF4/heparin antibodies (IgG/M/A; EIA) and their functional activity (HIPA) in 38 whole organ deceased donor liver transplant recipients. Additionally, demographic, clinical, donor- and recipient-specific parameters and laboratory findings (ALAT, ASAT, cholinesterase) were investigated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01654848
|Klinikum rechts der Isar der TU München|
|Munich, Germany, D-81675|
|Principal Investigator:||Volker Assfalg, MD||Klinikum rechts der Isar, Dept. of Surgery|